<?xml version="1.0" encoding="utf-8"?><api:response xmlns:api="http://www.symplectic.co.uk/publications/api"><api:version uri="https://mypublications.shef.ac.uk/" elements-version="6.15.0.3976" schema-version="6.13" product-name="myPublications"/><api:request href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1226"/><api:result><api:object category="publication" id="1226" last-affected-when="2024-04-01T00:37:06.19+01:00" last-modified-when="2024-04-01T00:37:06.19+01:00" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1226" created-when="2010-05-17T13:47:33.937+01:00" type-id="5" type-display-name="Journal article" type="journal-article"><api:privacy-level>Public</api:privacy-level><api:privacy-level-locked>false</api:privacy-level-locked><api:ever-approved>true</api:ever-approved><api:reporting-date-1>2000-08-22</api:reporting-date-1><api:allow-type-switching>true</api:allow-type-switching><api:records><api:record format="native" id="4211973" source-id="28" source-name="eprints" source-display-name="White Rose Research Online" id-at-source="115374" last-modified-when="2022-12-29T04:42:15.387+00:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The anti-vascular action of the tubulin binding agent combretastatin A-4 phosphate (CA-4-P) has been quantified in two types of murine tumour, the breast adenocarcinoma CaNT and the round cell sarcoma SaS. The functional vascular volume, assessed using a fluorescent carbocyanine dye, was significantly reduced at 18 h after CA-4-P treatment in both tumour types, although the degree of reduction was very different in the two tumours. The SaS tumour, which has a higher nitric oxide synthase (NOS) activity than the CaNT tumour, showed ~10-fold greater resistance to vascular damage by CA-4-P. This is consistent with our previous findings, which showed that NO exerts a protective action against this drug. Simultaneous administration of CA-4-P with a NOS inhibitor, Nω-nitro-L-arginine (L-NNA), resulted in enhanced vascular damage and cytotoxicity in both tumour types. Administration of diethylamine NO, an NO donor, conferred protection against the vascular damaging effects. Following treatment with CA-4-P, neutrophil infiltration into the tumours, measured by myeloperoxidase (MPO) activity, was significantly increased. Levels of MPO activity also correlated with the levels of vascular injury and cytotoxicity measured in both tumour types. Neutrophilic MPO generates free radicals and may therefore contribute to the vascular damage associated with CA-4-P treatment. MPO activity was significantly increased in the presence of L-NNA, suggesting that the protective effect of NO against CA-4-P-induced vascular injury may be, at least partially, mediated by limiting neutrophil infiltration. The data are consistent with the hypothesis that neutrophil action contributes to vascular injury by CA-4-P and that NO generation acts to protect the tumour vasculature against CA4-P-induced injury. The protective effect of NO is probably associated with an anti-neutrophil action.

</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Parkins</api:last-name><api:initials>CS</api:initials><api:first-names>CS</api:first-names><api:separate-first-names><api:first-name>C</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Holder</api:last-name><api:initials>AL</api:initials><api:first-names>AL</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hill</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1361</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1361"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1361"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>combretastatin A-4 phosphate</api:keyword><api:keyword>vasculature</api:keyword><api:keyword>nitric oxide</api:keyword><api:keyword>neutrophil</api:keyword><api:keyword>SOLID TUMOR-THERAPY</api:keyword><api:keyword>ISCHEMIA-REPERFUSION INJURY</api:keyword><api:keyword>DEPENDENT MECHANISM</api:keyword><api:keyword>NORMAL-TISSUES</api:keyword><api:keyword>MURINE TUMORS</api:keyword><api:keyword>TUBULIN</api:keyword><api:keyword>MYELOPEROXIDASE</api:keyword><api:keyword>AGENTS</api:keyword><api:keyword>TOXICITY</api:keyword><api:keyword>RADICALS</api:keyword></api:keywords></api:field><api:field name="notes" type="text" display-name="Other information"><api:text>©  2000, Cancer Research Campaign. From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.
To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>811</api:begin-page><api:end-page>816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>9</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="public-url" type="text" display-name="Public URL"><api:text>https://eprints.whiterose.ac.uk/id/eprint/115374</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Cancer Research UK</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>https://doi.org/10.1054/bjoc.2000.1361</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>21</api:day><api:month>4</api:month><api:year>2017</api:year></api:date></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>18</api:day><api:month>5</api:month><api:year>2017</api:year></api:date></api:field><api:field name="repository-status" type="text" display-name="Availability"><api:text>Public</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field><api:files><api:file proprietary-id="https://eprints.whiterose.ac.uk/id/file/1692740"><api:filename>Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.pdf</api:filename><api:file-url>https://eprints.whiterose.ac.uk/115374/1/Determinants of anti-vascular action by combretastatin A-4 phosphate%3A role of nitric oxide.pdf</api:file-url><api:extension>pdf</api:extension><api:file-size>176575</api:file-size><api:mime-type>application/pdf</api:mime-type><api:checksum algorithm="md5">902720D297823CC4EE4DBA9582A31A08</api:checksum><api:file-version>Published version</api:file-version></api:file></api:files></api:native></api:record><api:record format="native" id="2319669" source-id="13" source-name="crossref" source-display-name="Crossref" id-at-source="10.1054/bjoc.2000.1361" last-modified-when="2023-06-03T08:03:43.6+01:00"><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Parkins</api:last-name><api:initials>CS</api:initials><api:first-names>CS</api:first-names><api:separate-first-names><api:first-name>C</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Holder</api:last-name><api:initials>AL</api:initials><api:first-names>AL</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hill</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1361</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1361"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1361"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1532-1827</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>811</api:begin-page><api:end-page>816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>9</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Springer Science and Business Media LLC</api:text></api:field><api:field name="publisher-url" type="text" display-name="Link 2"><api:text>http://dx.doi.org/10.1054/bjoc.2000.1361</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>23</api:day><api:month>5</api:month><api:year>2023</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field></api:native></api:record><api:record format="native" id="95613" source-id="7" source-name="scopus" source-display-name="Scopus" id-at-source="2-s2.0-0033817283" last-modified-when="2024-02-28T07:58:36.05+00:00"><api:citation-count>53</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The anti-vascular action of the tubulin binding agent combretastatin A-4 phosphate (CA-4-P) has been quantified in two types of murine tumour, the breast adenocarcinoma CaNT and the round cell sarcoma SaS. The functional vascular volume, assessed using a fluorescent carbocyanine dye, was significantly reduced at 18 h after CA-4-P treatment in both tumour types, although the degree of reduction was very different in the two tumours. The SaS tumour, which has a higher nitric oxide synthase (NOS) activity than the CaNT tumour, showed ~10-fold greater resistance to vascular damage by CA-4-P. This is consistent with our previous findings, which showed that NO exerts a protective action against this drug. Simultaneous administration of CA-4-P with a NOS inhibitor, N(ω)-nitro-L-arginine (L-NNA), resulted in enhanced vascular damage and cytotoxicity in both tumour types. Administration of diethylamine NO, an NO donor, conferred protection against the vascular damaging effects. Following treatment with CA-4-P, neutrophil infiltration into the tumours, measured by myeloperoxidase (MPO) activity, was significantly increased. Levels of MPO activity also correlated with the levels of vascular injury and cytotoxicity measured in both tumour types. Neutrophilic MPO generates free radicals and may therefore contribute tO the vascular damage associated with CA-4-P treatment. MPO activity was significantly increased in the presence of L-NNA, suggesting that the protective effect of NO against CA-4-P-induced vascular injury may be, at least partially, mediated by limiting neutrophil infiltration. The data are consistent with the hypothesis that neutrophil action contributes to vascular injury by CA-4-P and that NO generation acts to protect the tumour vasculature against CA4-P-induced injury. The protective effect of NO is probably associated with an anti-neutrophil action. (C) 2000 Cancer Research Campaign.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Parkins</api:last-name><api:initials>CS</api:initials><api:first-names>CS</api:first-names><api:separate-first-names><api:first-name>C</api:first-name><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7007108906</api:identifier></api:identifiers></api:person><api:person><api:last-name>Holder</api:last-name><api:initials>AL</api:initials><api:first-names>AL</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>L</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">57197005697</api:identifier></api:identifiers></api:person><api:person><api:last-name>Hill</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7402766290</api:identifier></api:identifiers></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address><api:address iso-country-code="FR"><api:line type="organisation">Sanofi S.A.</api:line><api:line type="city">Gentilly</api:line><api:line type="country">France</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7103344024</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">Mount Vernon Hospital</api:line><api:line type="city">Northwood</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="scopus-author-id">7005831992</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1361</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1361"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1361"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10952787</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>811</api:begin-page><api:end-page>816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:day>1</api:day><api:month>1</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Determinants of anti-vascular action by combretastatin A-4 phosphate: Role of nitric oxide</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field></api:native></api:record><api:record format="native" id="1226" source-id="2" source-name="pubmed" source-display-name="PubMed" id-at-source="10952787" last-modified-when="2020-04-28T21:26:19.497+01:00"><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The anti-vascular action of the tubulin binding agent combretastatin A-4 phosphate (CA-4-P) has been quantified in two types of murine tumour, the breast adenocarcinoma CaNT and the round cell sarcoma SaS. The functional vascular volume, assessed using a fluorescent carbocyanine dye, was significantly reduced at 18 h after CA-4-P treatment in both tumour types, although the degree of reduction was very different in the two tumours. The SaS tumour, which has a higher nitric oxide synthase (NOS) activity than the CaNT tumour, showed approximately 10-fold greater resistance to vascular damage by CA-4-P. This is consistent with our previous findings, which showed that NO exerts a protective action against this drug. Simultaneous administration of CA-4-P with a NOS inhibitor, N(omega)-nitro-L-arginine (L-NNA), resulted in enhanced vascular damage and cytotoxicity in both tumour types. Administration of diethylamine NO, an NO donor, conferred protection against the vascular damaging effects. Following treatment with CA-4-P, neutrophil infiltration into the tumours, measured by myeloperoxidase (MPO) activity, was significantly increased. Levels of MPO activity also correlated with the levels of vascular injury and cytotoxicity measured in both tumour types. Neutrophilic MPO generates free radicals and may therefore contribute to the vascular damage associated with CA-4-P treatment. MPO activity was significantly increased in the presence of L-NNA, suggesting that the protective effect of NO against CA-4-P-induced vascular injury may be, at least partially, mediated by limiting neutrophil infiltration. The data are consistent with the hypothesis that neutrophil action contributes to vascular injury by CA-4-P and that NO generation acts to protect the tumour vasculature against CA4-P-induced injury. The protective effect of NO is probably associated with an anti-neutrophil action.</api:text></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Parkins</api:last-name><api:initials>CS</api:initials><api:first-names>CS</api:first-names><api:separate-first-names><api:first-name>C</api:first-name><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="full">Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, UK.</api:line></api:address></api:addresses></api:person><api:person><api:last-name>Holder</api:last-name><api:initials>AL</api:initials><api:first-names>AL</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hill</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.ncbi.nlm.nih.gov/pubmed/10952787</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1361</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1361"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1361"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pmc">PMC2363526</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>Br J Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Angiogenesis Inhibitors</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Mammary Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh">Mice</api:keyword><api:keyword scheme="mesh">Neutrophils</api:keyword><api:keyword scheme="mesh">Nitric Oxide</api:keyword><api:keyword scheme="mesh">Nitric Oxide Synthase</api:keyword><api:keyword scheme="mesh">Peroxidase</api:keyword><api:keyword scheme="mesh">Sarcoma, Experimental</api:keyword><api:keyword scheme="mesh">Stilbenes</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="location" type="text" display-name="Country"><api:text>England</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>811</api:begin-page><api:end-page>816</api:end-page></api:pagination></api:field><api:field name="pii" type="text" display-name="PII"><api:text>S0007092000913612</api:text></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>9</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="record-made-public-at-source-date" type="date" display-name="Record made publicly available"><api:date><api:day>28</api:day><api:month>9</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Journal Article</api:item><api:item>Research Support, Non-U.S. Gov't</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field></api:native></api:record><api:record format="native" id="882322" source-id="18" source-name="epmc" source-display-name="Europe PubMed Central" id-at-source="MED:10952787" last-modified-when="2023-11-21T18:58:27.273+00:00"><api:citation-count>30</api:citation-count><api:native><api:field name="abstract" type="text" display-name="Abstract"><api:text>The anti-vascular action of the tubulin binding agent combretastatin A-4 phosphate (CA-4-P) has been quantified in two types of murine tumour, the breast adenocarcinoma CaNT and the round cell sarcoma SaS. The functional vascular volume, assessed using a fluorescent carbocyanine dye, was significantly reduced at 18 h after CA-4-P treatment in both tumour types, although the degree of reduction was very different in the two tumours. The SaS tumour, which has a higher nitric oxide synthase (NOS) activity than the CaNT tumour, showed approximately 10-fold greater resistance to vascular damage by CA-4-P. This is consistent with our previous findings, which showed that NO exerts a protective action against this drug. Simultaneous administration of CA-4-P with a NOS inhibitor, N(omega)-nitro-L-arginine (L-NNA), resulted in enhanced vascular damage and cytotoxicity in both tumour types. Administration of diethylamine NO, an NO donor, conferred protection against the vascular damaging effects. Following treatment with CA-4-P, neutrophil infiltration into the tumours, measured by myeloperoxidase (MPO) activity, was significantly increased. Levels of MPO activity also correlated with the levels of vascular injury and cytotoxicity measured in both tumour types. Neutrophilic MPO generates free radicals and may therefore contribute to the vascular damage associated with CA-4-P treatment. MPO activity was significantly increased in the presence of L-NNA, suggesting that the protective effect of NO against CA-4-P-induced vascular injury may be, at least partially, mediated by limiting neutrophil infiltration. The data are consistent with the hypothesis that neutrophil action contributes to vascular injury by CA-4-P and that NO generation acts to protect the tumour vasculature against CA4-P-induced injury. The protective effect of NO is probably associated with an anti-neutrophil action.</api:text></api:field><api:field name="addresses" type="address-list" display-name="Addresses"><api:addresses><api:address iso-country-code="GB"><api:line type="full">Tumour Microcirculation Group, Gray Laboratory Cancer Research Trust, Mount Vernon Hospital, Northwood, Middlesex, HA6 2JR, UK.</api:line></api:address></api:addresses></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Parkins</api:last-name><api:initials>CS</api:initials><api:first-names>CS</api:first-names><api:separate-first-names><api:first-name>C</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Holder</api:last-name><api:initials>AL</api:initials><api:first-names>AL</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hill</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1361</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1361"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1361"/></api:links></api:field><api:field name="eissn" type="text" display-name="eISSN"><api:text>1532-1827</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10952787</api:identifier><api:identifier scheme="pmc">PMC2363526</api:identifier></api:identifiers></api:field><api:field name="is-open-access" type="boolean" display-name="Open access"><api:boolean>true</api:boolean></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British journal of cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="mesh">Neutrophils</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Mice</api:keyword><api:keyword scheme="mesh">Sarcoma, Experimental</api:keyword><api:keyword scheme="mesh">Mammary Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh">Nitric Oxide</api:keyword><api:keyword scheme="mesh">Stilbenes</api:keyword><api:keyword scheme="mesh">Peroxidase</api:keyword><api:keyword scheme="mesh">Angiogenesis Inhibitors</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Nitric Oxide Synthase</api:keyword></api:keywords></api:field><api:field name="language" type="text" display-name="Language"><api:text>eng</api:text></api:field><api:field name="medium" type="text" display-name="Medium"><api:text>Print</api:text></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Open Access</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>811</api:begin-page><api:end-page>816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>9</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="publisher-licence" type="text" display-name="Publisher licence"><api:text>CC BY</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>23</api:day><api:month>8</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide.</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Research Support, Non-U.S. Gov't</api:item><api:item>research-article</api:item><api:item>Journal Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field><api:files><api:file proprietary-id="https://www.nature.com/articles/6691361.pdf"><api:file-url>https://www.nature.com/articles/6691361.pdf</api:file-url><api:extension>pdf</api:extension><api:is-open-access>true</api:is-open-access><api:file-version>Published version</api:file-version></api:file><api:file proprietary-id="https://europepmc.org/articles/PMC2363526?pdf=render"><api:file-url>https://europepmc.org/articles/PMC2363526?pdf=render</api:file-url><api:extension>pdf</api:extension><api:is-open-access>true</api:is-open-access><api:file-version>Published version</api:file-version></api:file></api:files></api:native></api:record><api:record format="native" id="2470798" source-id="10" source-name="dimensions" source-display-name="Dimensions" id-at-source="pub.1049184599" last-modified-when="2024-04-01T00:37:06.193+01:00"><api:citation-count>48</api:citation-count><api:native><api:field name="altmetric-attention-score" type="integer" display-name="Altmetric attention score"><api:integer>3</api:integer></api:field><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Parkins</api:last-name><api:initials>CS</api:initials><api:first-names>CS</api:first-names><api:separate-first-names><api:first-name>C</api:first-name><api:first-name>S</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Oxford</api:line><api:line type="city">Oxford</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01370066463.59</api:identifier></api:identifiers></api:person><api:person><api:last-name>Holder</api:last-name><api:initials>AL</api:initials><api:first-names>AL</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>L</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Oxford</api:line><api:line type="city">Oxford</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01262574017.67</api:identifier></api:identifiers></api:person><api:person><api:last-name>Hill</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Oxford</api:line><api:line type="city">Oxford</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.01351102051.48</api:identifier></api:identifiers></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Oxford</api:line><api:line type="city">Oxford</api:line><api:line type="country">United Kingdom</api:line></api:address><api:address iso-country-code="FR"><api:line type="organisation">Sanofi (France)</api:line><api:line type="city">Paris</api:line><api:line type="country">France</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0745300522.28</api:identifier></api:identifiers></api:person><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names><api:addresses><api:address iso-country-code="GB"><api:line type="organisation">University of Oxford</api:line><api:line type="city">Oxford</api:line><api:line type="country">United Kingdom</api:line></api:address></api:addresses><api:identifiers><api:identifier scheme="dimensions-researcher-id">ur.0736063251.63</api:identifier></api:identifiers></api:person></api:people></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1361</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1361"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1361"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="pubmed">10952787</api:identifier><api:identifier scheme="pmc">PMC2363526</api:identifier></api:identifiers></api:field><api:field name="field-citation-ratio" type="decimal" display-name="Field citation ratio"><api:decimal>4.66</api:decimal></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>British Journal of Cancer</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword scheme="for-2020">3214 Pharmacology and Pharmaceutical Sciences</api:keyword><api:keyword scheme="for-2020">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="hrcs-rac">5.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac">5 Development of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc">Cancer</api:keyword><api:keyword scheme="mesh">Angiogenesis Inhibitors</api:keyword><api:keyword scheme="mesh">Animals</api:keyword><api:keyword scheme="mesh">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh">Female</api:keyword><api:keyword scheme="mesh">Mammary Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh">Mice</api:keyword><api:keyword scheme="mesh">Neutrophils</api:keyword><api:keyword scheme="mesh">Nitric Oxide</api:keyword><api:keyword scheme="mesh">Nitric Oxide Synthase</api:keyword><api:keyword scheme="mesh">Peroxidase</api:keyword><api:keyword scheme="mesh">Sarcoma, Experimental</api:keyword><api:keyword scheme="mesh">Stilbenes</api:keyword></api:keywords></api:field><api:field name="online-publication-date" type="date" display-name="Online publication date"><api:date><api:day>22</api:day><api:month>8</api:month><api:year>2000</api:year></api:date></api:field><api:field name="open-access-status" type="text" display-name="Open access status"><api:text>Hybrid OA</api:text></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>811</api:begin-page><api:end-page>816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>9</api:month><api:year>2000</api:year></api:date></api:field><api:field name="publisher" type="text" display-name="Publisher"><api:text>Springer Nature</api:text></api:field><api:field name="record-created-at-source-date" type="date" display-name="Record created at source"><api:date><api:day>31</api:day><api:month>8</api:month><api:year>2017</api:year></api:date></api:field><api:field name="relative-citation-ratio" type="decimal" display-name="Relative citation ratio"><api:decimal>0.94</api:decimal></api:field><api:field name="title" type="text" display-name="Title"><api:text>Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field></api:native></api:record><api:record format="native" id="242227" source-id="11" source-name="wos-lite" source-display-name="Web of Science (Lite)" id-at-source="WOS:000089263700017" last-modified-when="2024-03-14T05:59:51.437+00:00"><api:citation-count>52</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Parkins</api:last-name><api:initials>CS</api:initials><api:first-names>CS</api:first-names><api:separate-first-names><api:first-name>C</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Holder</api:last-name><api:initials>AL</api:initials><api:first-names>AL</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hill</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="author-url" type="text" display-name="Link 1"><api:text>https://www.webofscience.com/api/gateway?GWVersion=2&amp;SrcApp=sheffield_elements_live&amp;SrcAuth=WosAPI&amp;KeyUT=WOS:000089263700017&amp;DestLinkType=FullRecord&amp;DestApp=WOS_CPL</api:text></api:field><api:field name="doi" type="text" display-name="DOI"><api:text>10.1054/bjoc.2000.1361</api:text><api:links><api:link type="doi" href="http://doi.org/10.1054/bjoc.2000.1361"/><api:link type="altmetric" href="http://www.altmetric.com/details.php?doi=10.1054/bjoc.2000.1361"/></api:links></api:field><api:field name="external-identifiers" type="identifier-list" display-name="External identifiers"><api:identifiers><api:identifier scheme="isidoc">353FG</api:identifier><api:identifier scheme="pubmed">10952787</api:identifier></api:identifiers></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>BRITISH JOURNAL OF CANCER</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>combretastatin A-4 phosphate</api:keyword><api:keyword>vasculature</api:keyword><api:keyword>nitric oxide</api:keyword><api:keyword>neutrophil</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>811</api:begin-page><api:end-page>816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:year>2000</api:year></api:date></api:field><api:field name="publication-status" type="text" display-name="Status"><api:text>Published</api:text></api:field><api:field name="title" type="text" display-name="Title"><api:text>Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide</api:text></api:field><api:field name="types" type="list" display-name="Sub types"><api:items><api:item>Article</api:item></api:items></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field></api:native></api:record><api:record format="native" id="25459" source-id="3" source-name="wos" source-display-name="Web of Science" id-at-source="WOS:000089263700017" last-modified-when="2014-07-25T11:08:14.817+01:00"><api:citation-count>36</api:citation-count><api:native><api:field name="authors" type="person-list" display-name="Authors"><api:people><api:person><api:last-name>Parkins</api:last-name><api:initials>CS</api:initials><api:first-names>CS</api:first-names><api:separate-first-names><api:first-name>C</api:first-name><api:first-name>S</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Holder</api:last-name><api:initials>AL</api:initials><api:first-names>AL</api:first-names><api:separate-first-names><api:first-name>A</api:first-name><api:first-name>L</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Hill</api:last-name><api:initials>SA</api:initials><api:first-names>SA</api:first-names><api:separate-first-names><api:first-name>S</api:first-name><api:first-name>A</api:first-name></api:separate-first-names></api:person><api:person><api:last-name>Chaplin</api:last-name><api:initials>DJ</api:initials><api:first-names>DJ</api:first-names><api:separate-first-names><api:first-name>D</api:first-name><api:first-name>J</api:first-name></api:separate-first-names></api:person><api:person><api:links><api:link type="elements/user" id="434" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/users/434"/></api:links><api:last-name>Tozer</api:last-name><api:initials>GM</api:initials><api:first-names>GM</api:first-names><api:separate-first-names><api:first-name>G</api:first-name><api:first-name>M</api:first-name></api:separate-first-names></api:person></api:people></api:field><api:field name="issn" type="text" display-name="ISSN"><api:text>0007-0920</api:text><api:links><api:link type="elements/journal" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662"/></api:links></api:field><api:field name="issue" type="text" display-name="Issue"><api:text>6</api:text></api:field><api:field name="journal" type="text" display-name="Journal"><api:text>BRIT J CANCER</api:text></api:field><api:field name="keywords" type="keyword-list" display-name="Keywords"><api:keywords><api:keyword>combretastatin A-4 phosphate</api:keyword><api:keyword>vasculature</api:keyword><api:keyword>nitric oxide</api:keyword><api:keyword>neutrophil</api:keyword><api:keyword>SOLID TUMOR-THERAPY</api:keyword><api:keyword>ISCHEMIA-REPERFUSION INJURY</api:keyword><api:keyword>DEPENDENT MECHANISM</api:keyword><api:keyword>NORMAL-TISSUES</api:keyword><api:keyword>MURINE TUMORS</api:keyword><api:keyword>TUBULIN</api:keyword><api:keyword>MYELOPEROXIDASE</api:keyword><api:keyword>AGENTS</api:keyword><api:keyword>TOXICITY</api:keyword><api:keyword>RADICALS</api:keyword></api:keywords></api:field><api:field name="pagination" type="pagination" display-name="Pagination"><api:pagination><api:begin-page>811</api:begin-page><api:end-page>816</api:end-page></api:pagination></api:field><api:field name="publication-date" type="date" display-name="Publication date"><api:date><api:month>9</api:month><api:year>2000</api:year></api:date></api:field><api:field name="title" type="text" display-name="Title"><api:text>Determinants of anti-vascular action by combretastatin A-4 phosphate: role of nitric oxide</api:text></api:field><api:field name="volume" type="text" display-name="Volume"><api:text>83</api:text></api:field></api:native></api:record></api:records><api:fields/><api:all-labels type="keyword-list"><api:keywords><api:keyword origin="record-data" source="eprints">combretastatin A-4 phosphate</api:keyword><api:keyword origin="record-data" source="eprints">vasculature</api:keyword><api:keyword origin="record-data" source="eprints">nitric oxide</api:keyword><api:keyword origin="record-data" source="eprints">neutrophil</api:keyword><api:keyword origin="record-data" source="eprints">SOLID TUMOR-THERAPY</api:keyword><api:keyword origin="record-data" source="eprints">ISCHEMIA-REPERFUSION INJURY</api:keyword><api:keyword origin="record-data" source="eprints">DEPENDENT MECHANISM</api:keyword><api:keyword origin="record-data" source="eprints">NORMAL-TISSUES</api:keyword><api:keyword origin="record-data" source="eprints">MURINE TUMORS</api:keyword><api:keyword origin="record-data" source="eprints">TUBULIN</api:keyword><api:keyword origin="record-data" source="eprints">MYELOPEROXIDASE</api:keyword><api:keyword origin="record-data" source="eprints">AGENTS</api:keyword><api:keyword origin="record-data" source="eprints">TOXICITY</api:keyword><api:keyword origin="record-data" source="eprints">RADICALS</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Angiogenesis Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Mammary Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Mice</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Neutrophils</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Nitric Oxide</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Nitric Oxide Synthase</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Peroxidase</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Sarcoma, Experimental</api:keyword><api:keyword scheme="mesh" origin="record-data" source="pubmed">Stilbenes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Neutrophils</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Mice</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Sarcoma, Experimental</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Mammary Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Nitric Oxide</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Stilbenes</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Peroxidase</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Angiogenesis Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="epmc">Nitric Oxide Synthase</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">3214 Pharmacology and Pharmaceutical Sciences</api:keyword><api:keyword scheme="for-2020" origin="record-data" source="dimensions">32 Biomedical and Clinical Sciences</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5.1 Pharmaceuticals</api:keyword><api:keyword scheme="hrcs-rac" origin="record-data" source="dimensions">5 Development of treatments and therapeutic interventions</api:keyword><api:keyword scheme="hrcs-hc" origin="record-data" source="dimensions">Cancer</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Angiogenesis Inhibitors</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Animals</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Antineoplastic Agents, Phytogenic</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Female</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Mammary Neoplasms, Experimental</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Mice</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Neutrophils</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Nitric Oxide</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Nitric Oxide Synthase</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Peroxidase</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Sarcoma, Experimental</api:keyword><api:keyword scheme="mesh" origin="record-data" source="dimensions">Stilbenes</api:keyword><api:keyword origin="record-data" source="wos-lite">combretastatin A-4 phosphate</api:keyword><api:keyword origin="record-data" source="wos-lite">vasculature</api:keyword><api:keyword origin="record-data" source="wos-lite">nitric oxide</api:keyword><api:keyword origin="record-data" source="wos-lite">neutrophil</api:keyword><api:keyword origin="record-data" source="wos">combretastatin A-4 phosphate</api:keyword><api:keyword origin="record-data" source="wos">vasculature</api:keyword><api:keyword origin="record-data" source="wos">nitric oxide</api:keyword><api:keyword origin="record-data" source="wos">neutrophil</api:keyword><api:keyword origin="record-data" source="wos">SOLID TUMOR-THERAPY</api:keyword><api:keyword origin="record-data" source="wos">ISCHEMIA-REPERFUSION INJURY</api:keyword><api:keyword origin="record-data" source="wos">DEPENDENT MECHANISM</api:keyword><api:keyword origin="record-data" source="wos">NORMAL-TISSUES</api:keyword><api:keyword origin="record-data" source="wos">MURINE TUMORS</api:keyword><api:keyword origin="record-data" source="wos">TUBULIN</api:keyword><api:keyword origin="record-data" source="wos">MYELOPEROXIDASE</api:keyword><api:keyword origin="record-data" source="wos">AGENTS</api:keyword><api:keyword origin="record-data" source="wos">TOXICITY</api:keyword><api:keyword origin="record-data" source="wos">RADICALS</api:keyword><api:keyword scheme="for" origin="issn-inferred">1112 Oncology and Carcinogenesis</api:keyword><api:keyword scheme="for" origin="issn-inferred">1117 Public Health and Health Services</api:keyword><api:keyword scheme="science-metrix" origin="issn-inferred">Oncology &amp; Carcinogenesis</api:keyword><api:keyword scheme="for-2020" origin="issn-inferred">3211 Oncology and carcinogenesis</api:keyword></api:keywords></api:all-labels><api:journal issn="0007-0920" href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/journals/973662" title="British Journal of Cancer"><api:records><api:record source-name="summary"><api:title>British Journal of Cancer</api:title></api:record></api:records></api:journal><api:relationships href="https://mypublications.shef.ac.uk:8091/secure-api/v6.13/publications/1226/relationships"/></api:object></api:result></api:response>